Oppenheimer initiated coverage on ImmunoGen with a new price target
$IMGN
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of ImmunoGen with a rating of Perform and set a new price target of $16.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/1/2023 | $25.00 → $31.00 | Buy → Neutral | Guggenheim |
| 11/20/2023 | $17.00 | Neutral | Goldman |
| 11/9/2023 | $25.00 | Buy | Deutsche Bank |
| 10/6/2023 | $16.00 | Perform | Oppenheimer |
| 5/3/2023 | $6.00 → $16.00 | Neutral → Overweight | Piper Sandler |
| 11/21/2022 | $10.00 | Buy | Truist |
| 9/9/2022 | $8.00 | Overweight | Barclays |
| 3/21/2022 | $9.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
15-12G - ImmunoGen, Inc. (0000855654) (Filer)
S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)
S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)